This Week in Brief Ozempic now drives 8.5% of Canada's public drug cost growth A single medication representing that much of total spending growth shows why generics can't come soon enough
Increased Vision Impairment Reports Linked to Semaglutide: Analysis of FDA Adverse Event Data
Your healthcare provider will assess your individual circumstances, including the reason for gallbladder removal and current digestive function, to determine whether weight loss injections represent a safe and appropriate treatment option for you
REDEFINE 2 (overweight/obesity with T2D) showed a 15.7% mean weight reduction and 73.5% achieving HbA1c 6.5%
These are four phenomenal days, rich with information and opportunities to connect right through the final session, Dr
For the full analysisinclusive of demographics, comorbidities, and social drivers of health data for the population, methodology, additional findings, limitations, and citationsyou can view the complete report on MedRxiv or directly within Truveta Studio